 Adipocyte-specific protein homologs |
| Within one aspect of the invention is provided an isolated polypeptide comprising a sequence of ... |
|
| Multi-functional chimeric hematopoietic receptor agonists |
| 1. A hematopoietic protein comprising; an amino acid sequence of the formula: Met-1 R1-L1-R2, Met-2 ... |
|
| DNA sequences comprising dystrophin minigenes and methods of use thereof |
| The present invention provides dystrophin minigenes that are significantly reduced in size without ... |
|
| Pharmaceutical composition and method for hypermetabolic weight loss |
| The present invention relates to a device, pharmaceutical composition and method for metabolizing ... |
|
| Method for manufacturing glycoproteins having human-type glycosylation |
| What is claimed is: 1. A method of manufacturing a glycoprotein having a sugar chain, comprising a ... |
|
| Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores |
| What is claimed is: 1. A compound of the formula: ##STR2## wherein: a is from 0 to 6,: b is from 0 ... |
|
| Nucleic acid analogue induced transcription of double stranded DNA |
| We claim: 1. A method of transcribing RNA, using a double-stranded DNA as a template, comprising: (... |
|
|
Human G-protein coupled receptor
| Details |
Inventors: Deleersnijder, Willy; Nys, Guy; Venema, Jakob; Berger, Claudia; ken, Christiane;
Assignee: Solvay Pharmaceuticals B.V. (CP Weesp, NL)
Primary Examiner: Ulm; John
Assistant Examiner:
Attorney, Agent or Firm: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.
The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the G-protein coupled receptor family, referred to as IGS4-family. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS4-gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS4 and the use of IGS4 polypeptides and polynucleotides and agonists or antagonists to the IGS4 receptor family in the treatment of PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease—e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophagal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers—e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, among others and diagnostic assays for such conditions. Preferred uses of the invention relate to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system. The invention also relates to the identification of the cognate ligand of the IGS4 polypeptides of the invention. High affinity binding to said IGS4 polypeptides is found for the neuropeptides known as neuromedin U. |
|
DETAILED DESCRIPTION What is claimed is: 1.
An isolated polynucleotide comprising a nucleotide sequence chosen from: a) a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7; b) a nucleotide sequence encoding a polypeptide according to SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8; c) a nucleotide sequence of the DNA insert contained in the deposit no.
CBS102221 or the deposit no.
CBS102222 at the Centraalbureau voor Schimmelcultures at Baarn the Netherlands; or d) a nucleotide sequence which is complimentary to the nucleotide sequence of (a) or (b) or (c).
2.
The polynucleotide of claim 1 wherein said polynucleotide comprises: a) the nucleotide sequence contained in SEQ ID NO: 1 encoding the polypeptide of SEQ ID NO: 2; b) the nucleotide sequence contained in SEQ ID NO: 3 encoding the polypeptide of SEQ ID NO: 4; c) the nucleotide sequence contained in SEQ ID NO: 5 encoding the polypeptide of SEQ ID NO: 6; or d) the nucleotide sequence contained in SEQ ID NO: 7 encoding the polypeptide of SEQ ID NO: 8.
3.
The isolated polynucleotide of claim 1 which is DNA or RNA.
4.
An isolated polynucleotide encoding a neuromedin receptor protein of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8, said protein exhibiting ligand binding for neuromedin U with a log EC50 value of at least below -6.
00.
5.
The isolated polynucleotide of claim 4 encoding a polypeptide, wherein said polypeptide is expressed in at least one of brain, skeletal muscle, cerebellum, testis, corpus callosum, spinal cord, substantia nigra, medulla, thalamus, caudate nucleus, pons, nucleus accumbens, fetal brain, stomach, heart, thyroid gland, lung, thymus, prostate, and trachea.
6.
The isolated polynucleotide of claim 4, wherein the neuromedin receptor protein is a mammalian neuromedin receptor protein and neuromedin U is at least one of neuromedin U-8, neuromedin U-23, and neuromedin U-25.
7.
An isolated polynucleotide encoding a neuromedin receptor protein of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, or SEQ ID NO: 8, wherein said protein exhibits ligand binding for neuromedin U with a log EC50 value of at least below -6
|
|
Gene Therapy 
